{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T21:08:53Z","timestamp":1775423333817,"version":"3.50.1"},"reference-count":91,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19-Ai42790"],"award-info":[{"award-number":["U19-Ai42790"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosbiology.org"],"crossmark-restriction":false},"short-container-title":["PLoS Biol"],"abstract":"<jats:p>Despite the rapid creation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines, the precise correlates of immunity against severe Coronavirus Disease 2019 (COVID-19) are still unknown. Neutralizing antibodies represent a robust surrogate of protection in early Phase III studies, but vaccines provide protection prior to the evolution of neutralization, vaccines provide protection against variants that evade neutralization, and vaccines continue to provide protection against disease severity in the setting of waning neutralizing titers. Thus, in this study, using an Ad26.CoV2.S dose-down approach in nonhuman primates (NHPs), the role of neutralization, Fc effector function, and T-cell immunity were collectively probed against infection as well as against viral control. While dosing-down minimally impacted neutralizing and binding antibody titers, Fc receptor binding and functional antibody levels were induced in a highly dose-dependent manner. Neutralizing antibody and Fc receptor binding titers, but minimally T cells, were linked to the prevention of transmission. Conversely, Fc receptor binding\/function and T cells were linked to antiviral control, with a minimal role for neutralization. These data point to dichotomous roles of neutralization and T-cell function in protection against transmission and disease severity and a continuous role for Fc effector function as a correlate of immunity key to halting and controlling SARS-CoV-2 and emerging variants.<\/jats:p>","DOI":"10.1371\/journal.pbio.3001609","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T18:06:23Z","timestamp":1651773983000},"page":"e3001609","update-policy":"https:\/\/doi.org\/10.1371\/journal.pbio.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates"],"prefix":"10.1371","volume":"20","author":[{"given":"Daniel Y.","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4815-7237","authenticated-orcid":true,"given":"Dansu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0775-6623","authenticated-orcid":true,"given":"Jingyou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noe B.","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"McMahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica N.","family":"Borducchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Lifton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Nampanya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-5684","authenticated-orcid":true,"given":"Lisa H.","family":"Tostanoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Pessaint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Van Ry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Finneyfrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyse","family":"Teow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renita","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7852-0135","authenticated-orcid":true,"given":"Mark G.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas A.","family":"Lauffenburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan H.","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-9215","authenticated-orcid":true,"given":"Galit","family":"Alter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"pbio.3001609.ref001","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","author":"E Dong","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"pbio.3001609.ref002","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"DS Khoury","year":"2021","journal-title":"Nat Med"},{"key":"pbio.3001609.ref003","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"KA Earle","year":"2021","journal-title":"Vaccine"},{"key":"pbio.3001609.ref004","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","author":"A Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref005","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","author":"J Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref006","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.","volume":"398","author":"MD Tanriover","year":"2021","journal-title":"Lancet"},{"key":"pbio.3001609.ref007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.","volume":"6","author":"NC Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"pbio.3001609.ref008","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.","volume":"397","author":"M Voysey","year":"2021","journal-title":"Lancet"},{"key":"pbio.3001609.ref009","article-title":"Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans","author":"G Alter","year":"2021","journal-title":"Nature"},{"key":"pbio.3001609.ref010","first-page":"1","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","author":"P Wang","year":"2021","journal-title":"Nature"},{"key":"pbio.3001609.ref011","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing Activity of BNT162b2-Elicited Serum","volume":"384","author":"Y Liu","year":"2021","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref012","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","article-title":"Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies","volume":"27","author":"D Planas","year":"2021","journal-title":"Nat Med"},{"key":"pbio.3001609.ref013","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"D Planas","year":"2021","journal-title":"Nature"},{"key":"pbio.3001609.ref014","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.vaccine.2019.10.048","article-title":"Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-na\u00efve infants","volume":"38","author":"SK Browne","year":"2020","journal-title":"Vaccine"},{"key":"pbio.3001609.ref015","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref016","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"LA Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref017","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.","author":"A Pegu","year":"2021","journal-title":"Science"},{"key":"pbio.3001609.ref018","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41422-020-0364-z","article-title":"Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques.","volume":"30","author":"C Shan","year":"2020","journal-title":"Cell Res"},{"key":"pbio.3001609.ref019","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","author":"ES Winkler","year":"2021","journal-title":"Cell"},{"key":"pbio.3001609.ref020","doi-asserted-by":"crossref","first-page":"e0253487","DOI":"10.1371\/journal.pone.0253487","article-title":"The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.","volume":"16","author":"CEZ Chan","year":"2021","journal-title":"PLoS ONE."},{"key":"pbio.3001609.ref021","article-title":"Fc-engineered antibody therapeutics with improved efficacy against COVID-19.","author":"J Ravetch","year":"2021","journal-title":"Res Sq."},{"key":"pbio.3001609.ref022","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"G Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"pbio.3001609.ref023","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-021-22958-8","article-title":"Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.","volume":"12","author":"S Dispinseri","year":"2021","journal-title":"Nat Commun"},{"key":"pbio.3001609.ref024","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.cell.2020.10.052","article-title":"Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality.","volume":"183","author":"T Zohar","year":"2020","journal-title":"Cell"},{"key":"pbio.3001609.ref025","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"A Grifoni","year":"2020","journal-title":"Cell"},{"key":"pbio.3001609.ref026","article-title":"Immunological memory to SARS-CoV-2 assessed for up to eight months after infection.","author":"JM Dan","year":"2020","journal-title":"bioRxiv"},{"key":"pbio.3001609.ref027","first-page":"2021","article-title":"Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees.","author":"A Tarke","year":"2021","journal-title":"bioRxiv"},{"key":"pbio.3001609.ref028","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cell.2015.10.027","article-title":"Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology","volume":"163","author":"AW Chung","year":"2015","journal-title":"Cell"},{"key":"pbio.3001609.ref029","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1016\/j.cell.2021.05.040","article-title":"Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques","volume":"184","author":"X He","year":"2021","journal-title":"Cell"},{"key":"pbio.3001609.ref030","doi-asserted-by":"crossref","article-title":"SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques.","author":"R Roozendaal","DOI":"10.1038\/s41467-021-26117-x"},{"key":"pbio.3001609.ref031","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0065-2776(08)60866-4","article-title":"Antibody Class Switching.","author":"J. Stavnezer","year":"1996","journal-title":"Adv Immunol"},{"key":"pbio.3001609.ref032","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fimmu.2018.00678","article-title":"The CD8 T Cell Response to Respiratory Virus Infections.","volume":"9","author":"ME Schmidt","year":"2018","journal-title":"Front Immunol"},{"key":"pbio.3001609.ref033","first-page":"2013","volume-title":"PLS path modeling with R.","author":"G. Sanchez","year":"2013"},{"key":"pbio.3001609.ref034","article-title":"Will SARS-CoV-2 variants of concern affect the promise of vaccines?","author":"RK Gupta","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"pbio.3001609.ref035","article-title":"SARS-CoV-2 Variants of Concern in the United States\u2014Challenges and Opportunities","volume":"1037","author":"RP Walensky","year":"2021","journal-title":"JAMA"},{"key":"pbio.3001609.ref036","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"RE Chen","year":"2021","journal-title":"Nat Med"},{"key":"pbio.3001609.ref037","article-title":"Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant","author":"C Graham","year":"2021","journal-title":"Immunity"},{"key":"pbio.3001609.ref038","article-title":"Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization.","author":"D Ho","journal-title":"bioRxiv"},{"key":"pbio.3001609.ref039","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.","volume":"182","author":"B Korber","year":"2020","journal-title":"Cell"},{"key":"pbio.3001609.ref040","first-page":"2020","article-title":"Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: Insights from linking epidemiological and genetic data.","author":"E Volz","year":"2021","journal-title":"medRxiv"},{"key":"pbio.3001609.ref041","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"H Tegally","year":"2021","journal-title":"Nature"},{"key":"pbio.3001609.ref042","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","article-title":"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.","volume":"372","author":"NR Faria","year":"2021","journal-title":"Science"},{"key":"pbio.3001609.ref043","author":"E Lasek-Nesselquist","journal-title":"The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State"},{"key":"pbio.3001609.ref044","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"LR Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"PM Folegatti","year":"2020","journal-title":"Lancet"},{"key":"pbio.3001609.ref046","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.","author":"S Wu","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"pbio.3001609.ref047","first-page":"682","article-title":"Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset.","volume":"2","author":"S Kalimuddin","year":"2021","journal-title":"Med (N Y)."},{"key":"pbio.3001609.ref048","article-title":"Functional Antibodies in COVID-19 Convalescent Plasma.","author":"JD Herman","year":"2021","journal-title":"medRxiv"},{"key":"pbio.3001609.ref049","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"K McMahan","year":"2021","journal-title":"Nature"},{"key":"pbio.3001609.ref050","doi-asserted-by":"crossref","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"AT Tan","year":"2021","journal-title":"Cell Rep"},{"key":"pbio.3001609.ref051","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Q-X Long","year":"2020","journal-title":"Nat Med"},{"key":"pbio.3001609.ref052","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"DM Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"pbio.3001609.ref053","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1136\/thoraxjnl-2020-216256","article-title":"Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19.","volume":"76","author":"A Saris","year":"2021","journal-title":"Thorax"},{"key":"pbio.3001609.ref054","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"M Liao","year":"2020","journal-title":"Nat Med"},{"key":"pbio.3001609.ref055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nrmicro.2016.60","article-title":"Opportunistic intruders: how viruses orchestrate ER functions to infect cells","volume":"14","author":"MS Ravindran","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"pbio.3001609.ref056","article-title":"mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.","author":"K Wu","year":"2021","journal-title":"bioRxiv"},{"key":"pbio.3001609.ref057","article-title":"National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants","author":"LJ Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref058","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"SA Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref059","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","article-title":"Spike mutation D614G alters SARS-CoV-2 fitness","volume":"592","author":"JA Plante","year":"2021","journal-title":"Nature"},{"key":"pbio.3001609.ref060","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cell.2020.11.020","article-title":"Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity","volume":"184","author":"E Volz","year":"2021","journal-title":"Cell"},{"key":"pbio.3001609.ref061","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","article-title":"SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo","volume":"370","author":"YJ Hou","year":"2020","journal-title":"Science"},{"key":"pbio.3001609.ref062","article-title":"Effects of B. 1.1. 7 and B. 1.351 on COVID-19 dynamics. A campus reopening study.","author":"K Linka","year":"2021","journal-title":"medRxiv"},{"key":"pbio.3001609.ref063","article-title":"Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant","author":"V Shinde","year":"2021","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref064","unstructured":"Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. [cited 7 May 2021]. Available from: https:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3."},{"key":"pbio.3001609.ref065","article-title":"Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants","author":"LJ Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref066","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.","author":"JL Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref067","article-title":"Plasma Neutralization of the SARS-CoV-2 Omicron Variant","author":"F Schmidt","year":"2021","journal-title":"N Engl J Med"},{"key":"pbio.3001609.ref068","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41421-022-00375-5","article-title":"Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination","volume":"8","author":"X Yu","year":"2022","journal-title":"Cell Discov"},{"key":"pbio.3001609.ref069","first-page":"eabn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera","author":"A Muik","year":"2022","journal-title":"Science"},{"key":"pbio.3001609.ref070","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.","author":"WF Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"pbio.3001609.ref071","doi-asserted-by":"crossref","DOI":"10.3390\/v14010079","article-title":"SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron.","volume":"14","author":"SF Ahmed","year":"2022","journal-title":"Viruses"},{"key":"pbio.3001609.ref072","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/d41586-022-00063-0","article-title":"\u201cKiller\u201d immune cells still recognize Omicron variant.","volume":"601","author":"H. Ledford","year":"2022","journal-title":"Nature"},{"key":"pbio.3001609.ref073","article-title":"Immunosequencing and epitope mapping reveal substantial preservation of the T cell immune response to Omicron generated by SARS-CoV-2 vaccines.","author":"DH May"},{"key":"pbio.3001609.ref074","article-title":"Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients.","author":"CH GeurtsvanKessel","year":"2021","journal-title":"bioRxiv"},{"key":"pbio.3001609.ref075","article-title":"SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron","author":"R Keeton","year":"2021","journal-title":"medRxiv"},{"key":"pbio.3001609.ref076","article-title":"Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant.","author":"J Liu","year":"2022","journal-title":"medRxiv"},{"key":"pbio.3001609.ref077","article-title":"Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms.","author":"Y Bartsch","year":"2021","journal-title":"medRxiv"},{"key":"pbio.3001609.ref078","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1473-3099(20)30232-2","article-title":"Viral dynamics in mild and severe cases of COVID-19","volume":"20","author":"Y Liu","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"pbio.3001609.ref079","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"R W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"pbio.3001609.ref080","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3389\/fimmu.2019.01851","article-title":"A Sample-Sparing Multiplexed ADCP Assay.","volume":"10","author":"AL Butler","year":"2019","journal-title":"Front Immunol."},{"key":"pbio.3001609.ref081","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jim.2019.05.006","article-title":"A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis","volume":"471","author":"CB Karsten","year":"2019","journal-title":"J Immunol Methods"},{"key":"pbio.3001609.ref082","doi-asserted-by":"crossref","first-page":"112630","DOI":"10.1016\/j.jim.2019.07.002","article-title":"A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation","volume":"473","author":"S Fischinger","year":"2019","journal-title":"J Immunol Methods"},{"key":"pbio.3001609.ref083","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.chom.2018.07.009","article-title":"A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus","volume":"24","author":"BM Gunn","year":"2018","journal-title":"Cell Host Microbe"},{"key":"pbio.3001609.ref084","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"NB Mercado","year":"2020","journal-title":"Nature"},{"key":"pbio.3001609.ref085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jim.2012.09.007","article-title":"High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples","volume":"386","author":"EP Brown","year":"2012","journal-title":"J Immunol Methods"},{"key":"pbio.3001609.ref086","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jim.2017.01.010","article-title":"Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles","volume":"443","author":"EP Brown","year":"2017","journal-title":"J Immunol Methods"},{"key":"pbio.3001609.ref087","first-page":"2825","article-title":"Scikit-learn: Machine learning in Python.","volume":"12","author":"F Pedregosa","year":"2011","journal-title":"J Mach Learn Res"},{"key":"pbio.3001609.ref088","doi-asserted-by":"crossref","unstructured":"McKinney W, Others. Data structures for statistical computing in python. Proceedings of the 9th Python in Science Conference. Austin, TX; 2010. pp. 51\u201356.","DOI":"10.25080\/Majora-92bf1922-00a"},{"key":"pbio.3001609.ref089","doi-asserted-by":"crossref","DOI":"10.1201\/9780429447273","author":"C. Sievert","year":"2020","journal-title":"Interactive Web-Based Data Visualization with R, plotly and shiny"},{"key":"pbio.3001609.ref090","doi-asserted-by":"crossref","unstructured":"Hunter. Matplotlib: A 2D Graphics Environment. 2007;9:90\u20135.","DOI":"10.1109\/MCSE.2007.55"},{"key":"pbio.3001609.ref091","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python.","volume":"17","author":"P Virtanen","year":"2020","journal-title":"Nat Methods"}],"container-title":["PLOS Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3001609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T18:07:48Z","timestamp":1651774068000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pbio.3001609"}},"subtitle":[],"editor":[{"given":"Sarah L.","family":"Rowland-Jones","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":91,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pbio.3001609","relation":{},"ISSN":["1545-7885"],"issn-type":[{"value":"1545-7885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]}}}